Abstract 298P
Background
Cervical Cancer is one of the leading causes of cancer mortality in Indian women.Most of the women present in advanced stages of cervical cancer. Although CTRT remains the standard of care there were several challenges in implementation. In this study we assesed 3-year outcomes of LACC patients and the factors impacted the outcome.
Methods
We retrospectively analysed the records and follow up data of 131 patients of locally advanced cervical cancer registered in 2019. We noted the baseline characteristics include demographic data, comorbidities, histology and stage, treatment details, follow up data which include their disease status, death. Table: 298P
Baseline characterstics
Variables | N=131 | (%) | |
Comorbidities | |||
Diabetes Mellitus | 19 | 14.5 | |
Hypertension | 18 | 13.7 | |
Others | 16 | 12.2 | |
None | 78 | 59.5 | |
ECOG | |||
1 | 98 | 74.8 | |
2 | 29 | 22.1 | |
3 | 4 | 3.1 | |
Histology | |||
Squamous Cell Carcinoma | 121 | 92.4 | |
Adenocarcinoma | 6 | 4.6 | |
Others | 4 | 3.1 | |
Stage (FIGO 2018) | |||
IB | 8 | 6.1 | |
IIA | 5 | 3.8 | |
IIB | 47 | 35.9 | |
IIIA | 6 | 4.6 | |
IIIB | 47 | 35.9 | |
IIIC1 | 9 | 6.9 | |
IIIC2 | 3 | 2.3 | |
IVA | 6 | 4.6 |
Results
The median follow-up time was 45.5 months (IQR - 39.7-47.4). 5 patients had defaulted radiotherapy, 5 defaulted brachytherapy and 9 deferred brachytherapy. The average time from diagnosis to start of treatment is 109 days. 3-year OS was 78.6%. Stage-wise survival was IB (100%), IIA (100%), IIB (78.7%), IIIA (83.3%), IIIB (78.7%), IIIC (66.6%) & IVA (50%). 82.4% in CTRT patients and 72.4% in RT alone were alive. Dose >85Gy resulted in better local control and survival. The 3-year OS of patients with Overall Treatment Time <56 days is 89.1% while OTT >56 days is 80.7% (p=0.215).
Conclusions
The findings of this study highlighted the importance of concurrent chemoradiation in locally advanced cervical cancer. Doses >85 Gy to the disease and OTT <56 days showed better outcomes. Strategies to improve compliance to CTRT and image-guided adaptive brachytherapy will help in improved local control and survival. In low-middle income countries, these outcomes are also impacted by non-compliance and long wait-list to treatment, which is often due to logistical and socio-cultural barriers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract